Transforming Diabetes Care: Pharmacist-Led Education and Its Impact on Patient Knowledge, Self-Management, and Health Outcomes

NCT06807333 | Not Yet Recruiting

• 1 other identifier: 318-24
• Study Type: interventional
• Target: 385
• Locations: 1 country
• Sites: 1

Brief Summary

This interventional study is to evaluate the impact of pharmacist-led education on diabetic patients' knowledge, self-management, and overall health outcomes. Participants in this study will attend pharmacist-led educational sessions designed to improve their understanding of diabetes and self-care practices. Researchers will assess changes in patients' knowledge, self-management behaviors, and clinical health markers before and after the intervention. The study will compare pre- and post-intervention results to determine the effectiveness of pharmacist-led education in transforming diabetes care.

Conditions

Diabetes Mellitus

Keywords

Pharmacist; Patient Knowledge; Self-Management; Health Outcome; HbA1c

Outcome Measures

Primary Outcomes (3)

• Diabetes Knowledge Score(DKQ-24)

  Patient's diabetes knowledge will be assessed using the Diabetes Knowledge Questionnaire (DKQ). The DKQ is a tool used to evaluate a patient's understanding of diabetes, including aspects such as blood sugar control, diet, exercise, and medication management. It consists of close-ended questions, with scores ranging from 0 to 100, where a higher score indicates a better level of knowledge regarding diabetes management.

  3 months

• Diabetes Management Self-Efficacy Score (DMSQ-16)

  Patient's diabetes self-management will be assessed using the Diabetes Self-Management Questionnaire (DMSQ). The DMSQ is a tool used to evaluate a patient's ability to manage their diabetes through self-care practices, including diet, physical activity, blood sugar monitoring, and medication adherence. It consists of close-ended questions, with scores ranging from 0 to 100, where a higher score reflects better self-management behaviors in managing diabetes.

  3 months

• HbA1C Levels (%)

  Patient's health outcomes will be assessed using HbA1c levels. HbA1c (glycated hemoglobin) is a blood test used to measure a patient's average blood sugar level over the past 3 months. It is a key indicator of diabetes management and glycemic control. The HbA1c level is reported as a percentage, with lower percentages indicating better control of blood sugar. A target HbA1c level of less than 7% is typically recommended for most diabetic patients. The score can range from high percentages (indicating poor control) to lower percentages (indicating better glycemic control).

  3 months

Study Arms (1)

Interventional Group

EXPERIMENTAL

Lifestyle Modifications: Education on healthy meal choices and physical activity to support diabetes management. Disease Education: In-depth information on diabetes, blood sugar control, and the prevention of complications. Self-Management Tools: Provision of blood glucose monitoring charts and practical strategies for daily diabetes care. Counseling: Personalized counseling to address emotional aspects, stress management, and confidence in managing diabetes.

Behavioral: Pharmacist led Education

Interventions

Pharmacist led Education BEHAVIORAL

Pharmacist-led education for diabetic patients focuses on enhancing their understanding of the disease, improving self-management skills, and promoting better health outcomes. The education covers key aspects of diabetes, such as the importance of blood sugar control, the role of diet and exercise, and how to monitor blood glucose levels. Patients are also taught effective self-management strategies, including how to make healthy food choices, incorporate physical activity into daily routines, and manage potential complications. By providing tailored education, pharmacists aim to empower patients to take an active role in their care, which can lead to improved disease management, better glycemic control, and reduced risk of complications.

Interventional Group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• We will include all confirmed diabetic patients who visit the SIH endocrinology OPD Clinic during the study duration.
• Both male and female patients visiting the Endocrinology Unit of the hospital will be eligible.
• Patients with HbA1c levels greater than 8% will be included.
• Both follow-up and newly diagnosed patients will be considered.
• Patients who sign the informed consent form will be enrolled in the study.

You may not qualify if:

• We will exclude patients with gestational diabetes mellitus (GDM).
• Patients with central obesity will not be included in the study.
• Type 1 diabetes mellitus (DM) patients under the age of 20 will be excluded.
• Patients with inadequate medical history will be excluded from participation.
• Patients with HbA1c levels less than 8% will not be included.
• Patients who do not provide informed consent or express a lack of interest in the study will be excluded.

Sponsors & Collaborators

• Shifa International Hospital: lead

Study Sites (1)

Shifa International Hospital

Islamabad, Islamabad, 44000, Pakistan

Location

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Iqra Farooq, Mphil

  Shifa International Hospital

  STUDY DIRECTOR

• Sara Ghulam Yahya, Ms.

  Shifa International Hospital

  PRINCIPAL INVESTIGATOR

• Faiza Abbas, Pharm-D

  Shifa International Hospital

  STUDY CHAIR

• Matti Ullah, PhD

  Hamdard University Islamabad Campus

  STUDY CHAIR

• Salwa Ahsan

  Shifa International Hospital

  STUDY CHAIR

• Osama Ishtiaq, Endocrinologist

  Shifa International Hospital

  STUDY CHAIR

Central Study Contacts

Iqra Farooq, Mphil

CONTACT

03335644661; iqra0989@gmail.com

Matti Ullah, PhD

CONTACT

03315056501; mattiullah123@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: Participants will be entertained as part of their regular appointment for prescription filling without any information of which group they are assigned in.
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Pharmacist

Study Record Dates

• First Submitted: January 29, 2025
• First Posted: February 4, 2025
• Study Start: February 1, 2025
• Primary Completion: May 30, 2025
• Study Completion: July 31, 2025
• Last Updated: February 4, 2025

Record last verified: 2025-01

Locations

PA (1)